With 0.94 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.86 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $16.07 whereas the lowest price it dropped to was $15.3636. The 52-week range on VRDN shows that it touched its highest point at $27.20 and its lowest point at $9.90 during that stretch. It currently has a 1-year price target of $37.86. Beta for the stock currently stands at 0.46.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VRDN was up-trending over the past week, with a rise of 10.89%, but this was up by 12.30% over a month. Three-month performance surged to 25.61% while six-month performance fell -17.11%. The stock lost -17.11% in the past year, while it has gained 30.67% so far this year. A look at the trailing 12-month EPS for VRDN yields -4.05 with Next year EPS estimates of -3.80. For the next quarter, that number is -1.01. This implies an EPS growth rate of -8.15% for this year and 6.71% for next year. EPS is expected to grow by 18.32% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 31.28%.
Float and Shares Shorts:
At present, 81.59 million VRDN shares are outstanding with a float of 73.61 million shares on hand for trading. On 2025-06-13, short shares totaled 11.34 million, which was 1388.9999999999998 higher than short shares on 1747267200. In addition to Mr. Stephen F. Mahoney J.D., MBA as the firm’s CEO, President & Director, Mr. Seth Harmon serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 1.14228 of VRDN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, VRDN reported revenue of $72000.0 and operating income of -$93866000.0. The EBITDA in the recently reported quarter was -$86209000.0 and diluted EPS was -$0.87.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VRDN since 11 analysts follow the stock currently. There are 10 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VRDN analysts setting a high price target of 61.0 and a low target of 19.0, the average target price over the next 12 months is 38.3125. Based on these targets, VRDN could surge 283.89% to reach the target high and rise by 19.57% to reach the target low. Reaching the average price target will result in a growth of 141.11% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.82257 being high and -$4.14029 being low. For VRDN, this leads to a yearly average estimate of -$4.00129.
